|
End-of-day quote
NSE India S.E.
21/09/2026
|
5-day change | 1st Jan Change | ||
| 2,009.30 INR | +0.27% |
|
+1.54% | +47.26% |
| 09-16 | Gilead Sciences Expands Licensing Agreements for HIV Treatment | MT |
| 08-06 | Emcure Pharmaceuticals Limited, Q1 2027 Earnings Call, Aug 06, 2026 |
Chart: Technical Analysis
NSE India S.E.INR
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| EMCURE | End-of-day quote | |
Bombay S.E.
| EMCURE | Delayed |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bullish | Bullish |
| Resistance | 2,009.6 | 2,009.6 | 2,326.78 |
| Spread/Res. | -0.01% | -0.01% | -13.64% |
| Spread/Supp. | +8.85% | +19.37% | +22.29% |
| Support | 1,845.9 | 1,683.3 | 1,643 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- EMCURE Stock
- Charts Emcure Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
